argenx SE ARGX
EURONEXT · Belgium · Health Technology
€850.20+3.40 (+0.40%)
Market open· · EUR · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market open· · EUR · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
European equities traded in the US as American depositary receipts were trending lower late Wednesda
New data show deepening improvement in ocular MG and sustained one-year efficacy in anti-AChR antibody-negative MG – broadening VYVGART's potential to treat all MG patientsReal-world evidence from more than 1,100 U.S. MG patients indicates the value of treating earlier with VYVGART Long-term data reinforce VYVGART’s consistent safety and efficacy profile in CIDP, and Phase 4 switch data support the feasibility of a direct, one-week transition from IVIg Empasiprubart Phase 2 study results in MMN
BOSTON, September 29, 2026--Ginkgo Datapoints and Apheris welcome AbbVie, argenx, Lundbeck, and Takeda as Founding Members of the Antibody Developability Consortium
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.